| entecavir / Generic mfg. |
| Completed | 1 | 240 | | interventionai treatment of hcc ;interventionai treatment of hcc+ Entecavir | Beijing You'an Hospital; Level of the institution：, Self-funding | liver cancer | | | | |
| Recruiting | 1 | 20 | | Phase 1: Entecavir Tab 1 mg(Synco (H.K.) Limited, Hong Kong); Phase 2: Entecavir Tab 1 mg (Bristol Myers Squibb Company, USA) ;Phase 1: Entecavir Tab 1 mg (Bristol Myers Squibb Company, USA); Phase 2: Entecavir Tab 1 mg(Synco (H.K.) Limited, Hong Kong) | Institute of Clinical Pharmacy, Central South University; Synco (H.K.) Limited, Hong Kong, Synco (H.K.) Limited, Hong Kong | Pharmacokinetics and Bioequivalence Study in human | | | | |
ChiCTR-IIR-16008284: Randomized, Double-blind, Parallel, Entecavir-controlled, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Morphothiadine Mesilate Capsules/Ritonavir Tablets in Patients with Chronic Hepatitis B |
|
|
| Recruiting | 1 | 24 | | 120mgGLS4/100mgRTV, QD ;240mgGLS4/100mgRTV, QD ;0.5mgETV, QD | Jilin University First Hosptal; Jilin university first hosptal, self-funding | chronic hepatitis B | | | | |
ChiCTR-IIR-17011142: Two-treatment, two-cycle, two-period, open, randomized crossover in-vivo bioequivalence study of entecavir tablets |
|
|
| Recruiting | 1 | 36 | | Phase 1: Entecavir Tab 1 mg (Beijing Baiao Pharmaceuticals Co., Ltd.); Phase 2: Entecavir Tab 1 mg (Bristol Myers Squibb Company, USA) ;Phase 1: Entecavir Tab 1 mg (Bristol Myers Squibb Company, USA); Phase 2: Entecavir Tab 1 mg (Beijing Baiao Pharmaceuticals Co., Ltd.) | Chinese PLA General Hospital; Chinese PLA General Hospital, Beijing Baiao Pharmaceuticals Co., Ltd. | Bioequivalence Study in human | | | | |
| Not yet recruiting | 1 | 28 | | investigational product | Xiyuan Hospital, CACMS; Shandong World Expo Jindu Pharmaceutical Co., Ltd, sponsor‘s funding | Not Applicable | | | | |
ChiCTR1800019497: Evaluation of open, single-center drug interaction test of TQ-A3334 tablets with entecavir dispersible tablets and tenofovir disoproxil fumarate tablets in healthy subjects |
|
|
| Not yet recruiting | 1 | 40 | | TQ-A3334 with entecavir dispersible tablets, tenofovir disoproxil fumarate tablets, and TQ-A3334 tablets with entecavir dispersible tablets or tenofovir disoproxil fumarate ;TQ-A3334 with entecavir dispersible tablets, tenofovir disoproxil fumarate tablets, and TQ-A3334 tablets with entecavir dispersible tablets or tenofovir disoproxil fumarate | The First Hospital of Jilin University; Chia Tai Tianqing Pharmaceutical Group Co, Ltd, Chia Tai Tianqing Pharmaceutical Group Co,Ltd | HBV | | | | |
ChiCTR2200059683: Pharmacokinetic interaction between hydronidone capsule and Entecavir capsule in Healthy Chinese subjects |
|
|
| Not yet recruiting | 1 | 12 | | Day 1 to 6: at about 07:30, 15:30, 23:30, take 60mg (2 tablets) of hydroxynitone capsule on an empty stomach with 200mL water; Day 7: Take 60mg (2 tablets) of hydroxynitone capsule orally on an empty stomach with 200mL water at around 07:30 Day 10 to 19: at about 07:30, entecavir capsu | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shanghai Genomics Inc. | Not applicable | | | | |
ChiCTR2000033331: Bioequivalence evaluation of entecavir tablets in healthy volunteers: a randomized open two-agent fasting single-dose, two-cycle, two-cross study |
|
|
| Recruiting | 1 | 28 | | T-R ;R-T | The Second Affiliated Hospital of Xingtai Medical College; Hunan Hengsheng Pharmaceutical Co., Ltd, Hunan Hengsheng Pharmaceutical Co.,Ltd | Chronic adult hepatitis B | | | | |
NCT05391360: Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study |
|
|
| Completed | 1 | 128 | RoW | Freethiadine tablets(part I), Freethiadine tablets (part II), Freethiadine placebo tablets, entecavir tablets | Sunshine Lake Pharma Co., Ltd. | Hepatitis B, Chronic | 01/23 | 01/23 | | |
NCT04638439: The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection |
|
|
| Recruiting | 1 | 20 | RoW | P1101 + Nivolumab + Entecavir, P1101 (Ropeginterferon alfa-2b) + Nivolumab + Entecavir | PharmaEssentia | Chronic Hepatitis B Infection, Chronic Hepatitis D Infection | 03/23 | 03/23 | | |
NCT05423106: A Single and Multiple Ascending Dose Study of JNJ-64457744 |
|
|
| Terminated | 1 | 60 | RoW | JNJ-64457744, Placebo, Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF), Entecavir (ETV) | Janssen Research & Development, LLC | Healthy, Hepatitis B, Chronic | 03/23 | 03/23 | | |
NCT05017116: A Single and Repeated Dose Escalation of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection |
|
|
| Completed | 1 | 40 | RoW | RBD1016, RBD1016 injection, Placebo, Entecavir | Suzhou Ribo Life Science Co. Ltd. | Chronic Hepatitis b | 10/23 | 10/23 | | |
NCT04536337: A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects |
|
|
| Recruiting | 1 | 336 | Europe, RoW | ALG-000184, Placebo, Entecavir | Aligos Therapeutics | Chronic Hepatitis B | 11/23 | 06/24 | | |
